Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept ...
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for ...
Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept
Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...